Advertisement
AMGN or BMY or PFE
Which Stock Would AI Choose? Amgen (AMGN) vs. Bristol Myers Squibb (BMY) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- AMGN is leaning on fast-growing drugs like Repatha and Evenity to offset biosimilar erosion in its denosumab franchise.
- BMY has delivered the strongest recent momentum of the group, with its "growth portfolio" now approaching 60% of revenue.
- PFE trades at a steep discount and pays the highest dividend yield, but faces a larger near-term patent cliff.
- All three are navigating losses of exclusivity (LOE), or patent expirations, while redirecting capital toward oncology, cardiometabolic, and rare-disease pipelines.
- Relative performance diverged sharply over the past year, with BMY and PFE posting double-digit gains while AMGN advanced more modestly.
Introduction
Amgen, Bristol Myers Squibb, and Pfizer are three of the largest names in global biopharmaceuticals, yet they currently sit at very different points in their growth cycles. Each is contending with patent expirations on legacy blockbusters while attempting to refocus on newer franchises. This stock comparison is relevant for investors and traders weighing growth momentum against income and value: BMY has been re-rating on pipeline execution, PFE is attracting yield-seeking and value-oriented buyers, and AMGN offers a blend of stability, dividends, and an emerging obesity opportunity. Understanding their contrasting business models, catalysts, and risk profiles helps clarify which profile best fits a given market outlook.
AMGN Overview and Recent Performance
Amgen is a diversified biotechnology leader spanning cardiovascular, bone health, inflammation, oncology, and rare disease. Recent market activity has been defined by a two-sided story. On one side, growth drivers such as Repatha, Evenity, and Uplizna are compounding quickly, while the denosumab franchise (Prolia and Xgeva) is eroding under biosimilar competition. Management has raised its full-year revenue and adjusted earnings per share (EPS, or profit allocated to each share) outlook, signaling confidence that new products can outpace older ones.
Sentiment has also been shaped by pipeline news. Positive Phase 3 data for dazodalibep in Sjögren's disease lifted the stock in recent weeks, while a failed competitor trial in the Lp(a) cardiovascular space briefly pressured shares over read-through concerns for Amgen's olpasiran. Investors are closely watching MariTide, the company's experimental obesity medicine, with pivotal data expected in 2027. Amgen's relatively rich valuation leaves less room for execution missteps.
BMY Overview and Recent Performance
Bristol Myers Squibb is a global pharmaceutical company with deep franchises in oncology, hematology, cardiovascular, and immunology. Its defining theme in recent months has been portfolio transformation: a "growth portfolio" led by Opdivo Qvantig (a subcutaneous form of the cancer immunotherapy Opdivo), Reblozyl, Breyanzi, and Camzyos is expanding at a double-digit pace, while legacy drugs such as Revlimid and Pomalyst face generic erosion. This mix pushed growth products to roughly 56% of first-half revenue, and management raised full-year guidance on the strength of the second quarter.
Recent market activity has favored BMY, with the stock gaining sharply over the past year and outperforming its industry and the broader market. Catalysts include the accelerated approval and positive Phase 3 data for Zenbexus (iberdomide) in multiple myeloma, plus anticipation around the milvexian cardiovascular program. The key trade-off is valuation: after a strong run, consensus price targets imply limited near-term upside even as sentiment remains constructive.
PFE Overview and Recent Performance
Pfizer is one of the world's largest pharmaceutical companies, with broad reach across oncology, vaccines, immunology, and primary care. After a prolonged post-pandemic reset, its shares have re-emerged as a defensive and income favorite, rising to a 52-week high in recent weeks on rotation into higher-yielding healthcare names. The dividend—among the most generous in the sector—and a low forward price-to-earnings (P/E) multiple, which compares a stock's price to expected profits, anchor the bull case.
Fundamentals remain mixed. COVID-19 products Comirnaty and Paxlovid continue to decline sharply, but ex-COVID revenue is growing, led by Padcev, Nurtec, and Lorbrena. Pfizer also struck a multibillion-dollar oncology collaboration aimed at refreshing its pipeline. The chief risk is the patent cliff: Eliquis and Xeljanz face U.S. exclusivity losses this year, with Ibrance and Xtandi to follow, creating pressure to prove that newer oncology and obesity assets can restore durable growth.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page curates a focused selection of automated strategies from a much larger universe of AI trading bots. Tickeron hosts hundreds of AI Trading Bots that trade thousands of different tickers, but only the strongest and most suitable for current market conditions earn a place in this curated section. Each bot operates with its own trading style, strategy, timeframe, performance record, and set of tickers, giving users a range of approaches rather than a one-size-fits-all signal. Exploring the page can help investors see how algorithmic systems are currently positioning across names like those compared here.
Head-to-Head Comparison
The three companies diverge most clearly on momentum, valuation, and risk. BMY offers the strongest recent relative performance and the clearest evidence that new products are replacing eroding ones, but its re-rating has compressed valuation headroom. PFE presents the most contrarian setup: a high yield, a discounted forward multiple, and rising momentum, balanced against the most imminent and concentrated patent cliff of the three. AMGN sits between them, combining reliable dividend growth and broad diversification with a premium valuation and an obesity catalyst that remains years from commercialization.
Sector exposure also differs. AMGN's growth is broad but leans cardiovascular and bone health; BMY is heavily weighted toward oncology and hematology; PFE spans vaccines, oncology, and primary care with residual COVID exposure. For valuation-sensitive investors, PFE's low forward P/E stands out; for trend-following traders, BMY's momentum and earnings beats are notable; for those prioritizing stability, AMGN's diversified, dividend-paying profile may appeal.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would most likely favor BMY at present. Its trend has been the most consistent of the three, supported by consecutive earnings beats, upward guidance revisions, and a widening contribution from growth products. These are the kinds of signals—persistent momentum, improving fundamentals, and tangible catalysts—that algorithmic systems tend to weight heavily. AMGN shows strength but trades at a richer valuation with key data still ahead, while PFE's appeal rests more on yield and a value re-rating that is not yet fully confirmed by earnings growth. This assessment is probabilistic and reflects current conditions rather than a definitive forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AMGN in upward trend: 10-day moving average broke above 50-day moving average on October 16, 2026
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AMGN as a result. In 45 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for AMGN just turned positive on September 24, 2026. Looking at past instances where AMGN's MACD turned positive, the stock continued to rise in 27 of 47 cases over the following month. The odds of a continued upward trend are 57%.
AMGN moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 189 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 151 of 272 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Bearish Trend Analysis
The 10-day RSI Indicator for AMGN moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 26 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
AMGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.318) is normal, around the industry mean (-2.799). P/E Ratio (27.081) is within average values for comparable stocks, (21.101). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.041) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
BMY in downward trend: price dove below 50-day moving average on October 23, 2026
BMY moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend. In 35 of 44 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for BMY crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
BMY broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BMY entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BMY's RSI Indicator exited the oversold zone, 14 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 47%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on BMY as a result. In 46 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 51%.
The Moving Average Convergence Divergence (MACD) for BMY just turned positive on October 16, 2026. Looking at past instances where BMY's MACD turned positive, the stock continued to rise in 29 of 50 cases over the following month. The odds of a continued upward trend are 58%.
Following a +6.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in 174 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 31 (best 1 - 100 worst), indicating outstanding price growth. BMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 69 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 72 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.627) is normal, around the industry mean (-2.799). P/E Ratio (13.482) is within average values for comparable stocks, (21.101). BMY's Projected Growth (PEG Ratio) (17.786) is slightly higher than the industry average of (5.738). Dividend Yield (0.041) settles around the average of (0.041) among similar stocks. P/S Ratio (2.642) is also within normal values, averaging (4.033).
PFE in +1.27% Uptrend, rising for three consecutive days on October 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PFE advanced for three days, in 149 of 278 cases, the price rose further within the following month. The odds of a continued upward trend are 54%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on PFE as a result. In 41 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 47%.
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on October 14, 2026. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in 17 of 43 cases over the following month. The odds of a continued upward trend are 40%.
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 14 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 52%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
PFE broke above its upper Bollinger Band on September 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PFE entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 17 (best 1 - 100 worst), indicating outstanding price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.009) is normal, around the industry mean (-2.799). P/E Ratio (39.000) is within average values for comparable stocks, (21.101). Projected Growth (PEG Ratio) (13.137) is also within normal values, averaging (5.738). Dividend Yield (0.057) settles around the average of (0.041) among similar stocks. P/S Ratio (2.469) is also within normal values, averaging (4.033).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.
AMGN | BMY | PFE | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 69 | 35 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 80 Overvalued | 94 Overvalued | 93 Overvalued | |
PROFIT vs RISK RATING 1..100 | 5 | 72 | 100 | |
SMR RATING 1..100 | 15 | 22 | 83 | |
PRICE GROWTH RATING 1..100 | 10 | 31 | 17 | |
P/E GROWTH RATING 1..100 | 25 | 69 | 3 | |
SEASONALITY SCORE 1..100 | 75 | 75 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (80) in the Biotechnology industry is in the same range as PFE (93) in the Pharmaceuticals Major industry, and is in the same range as BMY (94) in the Pharmaceuticals Major industry. This means that AMGN's stock grew similarly to PFE’s and similarly to BMY’s over the last 12 months.
AMGN's Profit vs Risk Rating (5) in the Biotechnology industry is significantly better than the same rating for BMY (72) in the Pharmaceuticals Major industry, and is significantly better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that AMGN's stock grew significantly faster than BMY’s and significantly faster than PFE’s over the last 12 months.
AMGN's SMR Rating (15) in the Biotechnology industry is in the same range as BMY (22) in the Pharmaceuticals Major industry, and is significantly better than the same rating for PFE (83) in the Pharmaceuticals Major industry. This means that AMGN's stock grew similarly to BMY’s and significantly faster than PFE’s over the last 12 months.
AMGN's Price Growth Rating (10) in the Biotechnology industry is in the same range as PFE (17) in the Pharmaceuticals Major industry, and is in the same range as BMY (31) in the Pharmaceuticals Major industry. This means that AMGN's stock grew similarly to PFE’s and similarly to BMY’s over the last 12 months.
PFE's P/E Growth Rating (3) in the Pharmaceuticals Major industry is in the same range as AMGN (25) in the Biotechnology industry, and is significantly better than the same rating for BMY (69) in the Pharmaceuticals Major industry. This means that PFE's stock grew similarly to AMGN’s and significantly faster than BMY’s over the last 12 months.
| AMGN | BMY | PFE | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 57% | 2 days ago 47% | 2 days ago 52% |
| Stochastic ODDS (%) | 2 days ago 47% | 2 days ago 54% | 2 days ago 61% |
| Momentum ODDS (%) | 2 days ago 62% | 2 days ago 51% | 2 days ago 47% |
| MACD ODDS (%) | 2 days ago 57% | 2 days ago 58% | 2 days ago 40% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 56% | 2 days ago 54% |
| TrendMonth ODDS (%) | 2 days ago 60% | 2 days ago 58% | 2 days ago 49% |
| Advances ODDS (%) | 10 days ago 61% | 10 days ago 56% | 9 days ago 54% |
| Declines ODDS (%) | 6 days ago 47% | 6 days ago 54% | 20 days ago 56% |
| BollingerBands ODDS (%) | 2 days ago 40% | 2 days ago 55% | 2 days ago 52% |
| Aroon ODDS (%) | 2 days ago 56% | 2 days ago 52% | 2 days ago 66% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green while BMY’s FA Score has 2 green FA rating(s), and PFE’s FA Score reflects 2 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- BMY’s FA Score: 2 green, 3 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 6 TA indicator(s) are bullish while BMY’s TA Score has 4 bullish TA indicator(s), and PFE’s TA Score reflects 3 bullish TA indicator(s).
- AMGN’s TA Score: 6 bullish, 4 bearish.
- BMY’s TA Score: 4 bullish, 6 bearish.
- PFE’s TA Score: 3 bullish, 5 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +1.57% price change this week, while BMY (@Pharmaceuticals: Major) price change was +2.90% , and PFE (@Pharmaceuticals: Major) price fluctuated +1.52% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.08%. For the same industry, the average monthly price growth was -4.91%, and the average quarterly price growth was +4.21%.
Reported Earning Dates
AMGN is expected to report earnings on Nov 03, 2026.
BMY is expected to report earnings on Oct 29, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.08% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.